TourniTek is the first pre-hospital treatment for emergencies leading to amputation and the first to combine the preservative properties of cooling with the circulatory control of a traditional tourniquet. TourniTek is designed to substantially extend the pre-treatment timeline by cooling the core temperature of the limb. This increases the window of time in which to seek treatment, preventing amputation and saving limbs.
Tourniquets are proven to save lives by preventing lethal blood loss. However, by restricting blood flow for the prolonged time required to transport an injured patient from the field to a surgical facility for treatment, tourniquet use often results in disability or amputation.
-2 provisional patents filed
-Awarded $1,500,000 contract from the U.S. military to fund R&D
-Partnered with both the U.S. and Canadian military for field testing, user testing, and lab testing in a paid pilot study.
-Military testing with TourniTek is scheduled to begin in mid-2020.
-Active prototype
-3 years of pre-clinical studies done
TourniTek received $1,249,671.00 from Air Force
TourniTek received $1,749,219.00 from Air Force
TourniTek received $74,263.00 from Air Force
TourniTek received $749,827.00 from Air Force
TourniTek received $49,590.00 from Air Force
| Agency | Total Amount |
|---|---|
| Air Force | $3,872,570.00 |
| Total | $3,872,570.00 |
